Sanofi rolls out new Fluzone shots; Alexion's Soliris driving myasthenia gravis market growth;

> Sanofi's ($SNY) vaccines division shipped its first doses of Fluzone for the 2015-2016 influenza season in the U.S. Release

> Alexion's ($ALXN) rare disease drug Soliris could drive the value of the myasthenia gravis market to $550 million by 2024, GlobalData figures. Report

> Misuse of the anticoagulant warfarin is causing deaths and injuries in nursing homes, a ProPublica investigation found. Report

> Taiwan's pharma market is expected to rise to $8.4 billion by 2020, despite ongoing political tensions with China. Release

> Sarepta Therapeutics ($SRPT) is looking to buy another drug to treat Duchenne muscular dystrophy in its race with BioMarin Pharmaceutical ($BMRN) in the field. Report

And Finally... The FDA warned about the cardiovascular risks of NSAIDs last week, and experts now say they should be used sparingly. Report

Suggested Articles

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.